Opinion
How age-related macular degeneration can rob us of sight, and how to see clearly through it all
Have your parents or grandparents ever had trouble driving, reading or recognizing faces? They might be suffering from age-related macular degeneration, a progressive disease afflicting about 11 ...
Eye exercises to improve sight – is there any science behind them? An ophthalmologist explains why you shouldn’t buy the hype
You may have seen advertisements claiming to eliminate the need for eyeglasses through vision therapy or vision training – ...
BBC on MSN11d
How blind yoga is helping people with sight loss
The 60-minute classes, which are all done seated, include meditation, breathing techniques and mindfulness exercises ...
health.economictimes.indiatimes1d
“Spotlight on Diabetic Eye Disease: Early Detection can save sight”
Anjana RM, Unnikrishnan R, Deepa M, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB ...
FierceBiotech9d
FDA clears its first treatment for dry AMD, with LumiThera's light-based Valeda system
The FDA has cleared its first light-based therapy for dry age-related macular degeneration—which the agency described as ...
ophthalmologytimes4d
HuidaGene Therapeutics' IND application for HG202 for the treatment of nAMD cleared by FDA
The drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related ...
Pharmabiz10d
HuidaGene Therapeutics gets US FDA clearance for CRISPR/Cas13 RNA-editing HG202 for macular degeneration
HuidaGene Therapeutics gets US FDA clearance for CRISPR/Cas13 RNA-editing HG202 for macular degeneration: Shanghai Tuesday, November 5, 2024, 09:00 Hrs [IST] HuidaGene Therapeutic ...
Business Insider10d
Buy Rating on Adverum Biotechnologies Driven by Ixo-vec’s Promising Data and Potential Impact on AMD Treatment
Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet ...
HuidaGene Therapeutics Receives the First-Ever FDA Clearance of CRISPR/Cas13 RNA-Editing HG202 for Macular Degeneration
HuidaGene Therapeutics ("HuidaGene"), a global clinical-stage biotechnology company, announced that the U.S. FDA has cleared its investigational new drug (IND) application for HG202, the world's first ...